SeaCrest Wealth Management LLC purchased a new position in Stryker Corporation (NYSE:SYK) during the 4th quarter, Holdings Channel reports. The firm purchased 1,571 shares of the medical technology company’s stock, valued at approximately $243,000.

A number of other institutional investors have also modified their holdings of SYK. Suntrust Banks Inc. raised its position in Stryker by 1.4% in the second quarter. Suntrust Banks Inc. now owns 69,658 shares of the medical technology company’s stock worth $9,666,000 after acquiring an additional 974 shares in the last quarter. Cibc World Markets Corp raised its position in Stryker by 35.6% in the second quarter. Cibc World Markets Corp now owns 43,846 shares of the medical technology company’s stock worth $6,085,000 after acquiring an additional 11,518 shares in the last quarter. Advisor Group Inc. raised its position in Stryker by 3.0% in the second quarter. Advisor Group Inc. now owns 12,800 shares of the medical technology company’s stock worth $1,709,000 after acquiring an additional 377 shares in the last quarter. Roundview Capital LLC bought a new stake in Stryker in the second quarter worth about $654,000. Finally, Parametric Portfolio Associates LLC raised its position in Stryker by 5.9% in the second quarter. Parametric Portfolio Associates LLC now owns 707,292 shares of the medical technology company’s stock worth $98,158,000 after acquiring an additional 39,160 shares in the last quarter. Hedge funds and other institutional investors own 74.85% of the company’s stock.

SYK has been the topic of several recent analyst reports. Zacks Investment Research downgraded Stryker from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Robert W. Baird restated a “hold” rating and set a $161.00 price objective on shares of Stryker in a report on Friday, October 27th. Piper Jaffray Companies restated a “buy” rating and set a $156.00 price objective on shares of Stryker in a report on Friday, October 27th. Wells Fargo & Co boosted their price objective on Stryker from $160.00 to $166.00 in a report on Friday, October 27th. Finally, Stifel Nicolaus boosted their price objective on Stryker from $158.00 to $168.00 and gave the stock a “buy” rating in a report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $162.50.

In related news, Director Howard E. Cox, Jr. sold 7,400 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $164.09, for a total value of $1,214,266.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Graham A. Mclean sold 2,984 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $160.53, for a total value of $479,021.52. Following the completion of the sale, the insider now directly owns 9,100 shares of the company’s stock, valued at approximately $1,460,823. The disclosure for this sale can be found here. Insiders sold a total of 16,840 shares of company stock worth $2,749,989 in the last quarter. 7.40% of the stock is owned by corporate insiders.

Stryker Corporation (NYSE SYK) opened at $151.22 on Friday. The firm has a market capitalization of $55,450.76, a PE ratio of 56.43, a PEG ratio of 2.13 and a beta of 0.70. Stryker Corporation has a twelve month low of $122.28 and a twelve month high of $170.00. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.01. The company had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a return on equity of 24.55% and a net margin of 8.20%. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.78 EPS. sell-side analysts forecast that Stryker Corporation will post 7.12 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a $0.47 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.24%. Stryker’s dividend payout ratio is 70.15%.

WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/seacrest-wealth-management-llc-invests-243000-in-stryker-corporation-syk-stock/1859246.html.

Stryker Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.